Search Results for: HRAS

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel C6orf62 chromosome 6 open reading frame 62
Novel CCL4 C-C motif chemokine ligand 4
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Interleukin-10 signaling
Novel HBG1 hemoglobin subunit gamma 1
  • Factors involved in megakaryocyte development and platelet production
Novel IGF2 insulin like growth factor 2
  • Platelet degranulation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • IRS-related events triggered by IGF1R
  • SHC-related events triggered by IGF1R
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Beckwith-Wiedemann syndrome
  • Russell-Silver syndrome; Silver-Russell syndrome
  • Adrenal carcinoma
Novel INS insulin
  • Regulation of gene expression in beta cells
  • Insulin processing
  • Insulin processing
  • Synthesis, secretion, and deacylation of Ghrelin
  • Regulation of insulin secretion
  • COPI-mediated anterograde transport
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Amyloid fiber formation
  • Zinc
  • M-Cresol
  • Myristic acid
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Maturity onset diabetes of the young (MODY)
  • Type I diabetes mellitus
  • Permanent neonatal diabetes mellitus (PNDM)
Novel KCNQ1 potassium voltage-gated channel subfamily Q member 1
  • Voltage gated Potassium channels
  • Phase 3 - rapid repolarisation
  • Phase 2 - plateau phase
  • Enflurane
  • Promethazine
  • Miconazole
  • Bepridil
  • Dronedarone
  • Azimilide
  • ICA-105665
  • Isavuconazole
  • Type II diabetes mellitus
  • Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
  • Atrial fibrillation
  • Short QT syndrome
Novel ZFP36L2 ZFP36 ring finger protein like 2
ABR ABR activator of RhoGEF and GTPase
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • G alpha (12/13) signalling events
ACTG1 actin gamma 1
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Gap junction degradation
  • Formation of annular gap junctions
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • EPHB-mediated forward signaling
  • EPH-ephrin mediated repulsion of cells
  • Adherens junctions interactions
  • Adherens junctions interactions
  • Recycling pathway of L1
  • Recycling pathway of L1
  • VEGFA-VEGFR2 Pathway
  • Interaction between L1 and Ankyrins
  • Interaction between L1 and Ankyrins
  • Cell-extracellular matrix interactions
  • RHO GTPases activate IQGAPs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Clathrin-mediated endocytosis
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Copper
  • Artenimol
AFDN afadin, adherens junction formation factor
  • (5R)-2-sulfanyl-5-[4-(trifluoromethyl)benzyl]-1,3-thiazol-4(5H)-one
AGTR1 angiotensin II receptor type 1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Valsartan
  • Olmesartan
  • Losartan
  • Candesartan cilexetil
  • Eprosartan
  • Telmisartan
  • Irbesartan
  • Forasartan
  • Saprisartan
  • Tasosartan
  • CYT006-AngQb
  • Azilsartan medoxomil
  • Fimasartan
  • Angiotensin II
  • Candesartan
  • Renal tubular dysgenesis
ANAPC1 anaphase promoting complex subunit 1
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
ANKRD11 ankyrin repeat domain 11
ANKRD16 ankyrin repeat domain 16
ANKRD23 ankyrin repeat domain 23
ANKRD34B ankyrin repeat domain 34B
APBB1IP amyloid beta precursor protein binding family B member 1 interacting protein
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
ARAF A-Raf proto-oncogene, serine/threonine kinase
  • RAF activation
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by MRAS-complex mutants
  • ATP
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
ARFGAP1 ADP ribosylation factor GTPase activating protein 1
  • XBP1(S) activates chaperone genes
  • COPI-mediated anterograde transport
  • COPI-dependent Golgi-to-ER retrograde traffic
  • Clathrin-mediated endocytosis
ARHGAP10 Rho GTPase activating protein 10
  • Rho GTPase cycle
  • Regulation of PAK-2p34 activity by PS-GAP/RHG10

Page 1 out of 8 pages